Medisprof srl

Cluj-Napoca 400641

0 studies enrolling now · 13 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung, Early Breast Cancer, Gastric Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Locally Advanced Renal Cell Carcinoma, Locally Advanced Soft Tissue Sarcoma, Locally Advanced Urothelial Cancer, Metastatic Breast Cancer, Metastatic Clear-Cell Renal Cell Carcinoma, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Metastatic Renal Cell Carcinoma

Studies at this site

• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) — Completed
• A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma — Completed
• Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma — Completed
• A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) — Completed
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) — Completed
• An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol — Completed
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer — Stopped early
• A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma — Completed
• Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer — Completed
• IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma — Completed
• A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer — Stopped early